GELESIS HOLDINGS INC (GLS) Stock Price, Forecast & Analysis
USA - NYSE:GLS - US36850R2040 - Common Stock
GLS Key Statistics, Chart & Performance
The current stock price of GLS is 0.1586 USD. In the past month the price decreased by -33.92%. In the past year, price decreased by -96.82%.
GLS Latest News, Press Relases and Analysis
GLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About GLS
Company Profile
Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.
Company Info
GELESIS HOLDINGS INC
501 Boylston Street, Suite 6102
Boston MASSACHUSETTS US
Employees: 93
Phone: 18573277737.0
GELESIS HOLDINGS INC / GLS FAQ
What does GELESIS HOLDINGS INC do?
Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.
What is the current price of GLS stock?
The current stock price of GLS is 0.1586 USD. The price increased by 0.38% in the last trading session.
What is the dividend status of GELESIS HOLDINGS INC?
GLS does not pay a dividend.
What is the ChartMill technical and fundamental rating of GLS stock?
GLS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting GLS stock to perform?
8 analysts have analysed GLS and the average price target is 0.46 USD. This implies a price increase of 189.41% is expected in the next year compared to the current price of 0.1586.
Can you provide the growth outlook for GELESIS HOLDINGS INC?
The Revenue of GELESIS HOLDINGS INC (GLS) is expected to grow by 80.41% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is GELESIS HOLDINGS INC worth?
GELESIS HOLDINGS INC (GLS) has a market capitalization of 11.63M USD. This makes GLS a Nano Cap stock.
GLS Technical Analysis
GLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLS. GLS may be in some trouble as it scores bad on both profitability and health.
GLS Financial Highlights
Over the last trailing twelve months GLS reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GLS Forecast & Estimates
8 analysts have analysed GLS and the average price target is 0.46 USD. This implies a price increase of 189.41% is expected in the next year compared to the current price of 0.1586.
For the next year, analysts expect an EPS growth of 78.59% and a revenue growth 80.41% for GLS